Grifois, S.A. - GRFS STOCK NEWS

Grifols has commenced a randomized controlled clinical trial for its anti-SARS-CoV-2 hyperimmune globulin aimed at treating COVID-19. Funded by NIAID, this Phase 3 trial will assess safety, efficacy, and tolerability in 500 hospitalized adults across 58 hospitals in 18 countries. This treatment leverages convalescent plasma from recovered COVID-19 patients, potentially enhancing immune response to reduce severe illness risk. Grifols has quickly established a convalescent plasma collection program and is actively participating in over 25 COVID-19 initiatives.

Grifols has launched a clinical trial for its anti-SARS-CoV-2 hyperimmune globulin, aimed at treating COVID-19. This randomized controlled trial will assess the product's safety and efficacy in 500 hospitalized adults across 58 hospitals in 18 countries, including the U.S. and Spain. Funded by NIAID, the trial seeks to enhance immune responses when symptoms appear. Grifols leads multiple COVID-19 initiatives and has developed a robust plasma collection program to support treatment efforts during the pandemic.

Grifols has acquired a plasma fractionation plant in Montreal and 11 plasma collection centers in the U.S. from GC Pharma for a total of US$460 million. This move establishes Grifols as the only large-scale commercial manufacturer of plasma products in Canada, with an annual capacity of 1.5 million liters. The investment aims to enhance self-sufficiency in plasma-derived medicines in Canada and expand Grifols' plasma collection network. The transaction will significantly bolster Grifols' presence in North America, targeting a market known for high plasma consumption.

Grifols has acquired a plasma fractionation plant and purification facilities in Montreal, Canada, for US$370 million, along with 11 U.S.-based plasma centers for US$90 million. This investment, which does not require external financing, marks Grifols as the only large-scale plasma products manufacturer in Canada, enhancing its capacity to produce essential medicines. The acquisition supports Canada's self-sufficiency in plasma-derived therapies and aligns with Grifols' strategy for international growth, particularly in North America, where plasma consumption rates are high.

Grifols (NASDAQ: GRFS) announced its acquisition of Alkahest, Inc. for $146 million on a debt-free basis. The deal aims to leverage Alkahest's expertise in the human plasma proteome to develop innovative therapies for age-related diseases. The transaction is pending antitrust approval and expected to close in early 2021. Alkahest has identified over 8,000 proteins that could lead to new therapeutics and diagnostics. This acquisition aligns with Grifols' mission to enhance its research and development capabilities in plasma-derived medicines.

Grifols has announced its acquisition of Alkahest, Inc. for $146 million, aimed at enhancing its research and development capabilities for age-related diseases. The transaction, debt-free and requiring no additional financing, is subject to antitrust approval and expected to finalize in early 2021. Alkahest specializes in therapies targeting the aging plasma proteome, with over 8,000 proteins identified, promising innovative therapeutic avenues. This strategic move is anticipated to provide synergies in drug development for unmet medical needs associated with aging.

Grifols has successfully delivered the first batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials, aimed at providing passive immunity against COVID-19. This therapy, developed from convalescent plasma, will undergo safety and efficacy trials this summer. Grifols' initiative is backed by collaborations with U.S. health agencies, including the FDA and NIH, with previous experience from the Ebola outbreak enhancing their response. This positions Grifols as a key player in addressing current and future viral threats through innovative therapies.

Grifols announced the publication of the AMBAR study results in a prestigious journal, demonstrating that plasma protein replacement therapy can delay cognitive decline in Alzheimer's patients. The study, which followed patients for 14 months, showed significant improvements compared to a control group, indicating the potential of plasma-derived therapies in addressing Alzheimer's disease. Grifols emphasizes its commitment to expanding research in this area, aiming to develop new therapies for Alzheimer's and other degenerative diseases.

Grifols has acquired a 10% stake in Bloodbuy, a cloud-based marketplace enhancing blood component distribution in the U.S. This strategic investment aims to improve access to vital blood products for hospitals and healthcare providers, addressing supply and demand challenges exacerbated by COVID-19. Grifols will gain a seat on Bloodbuy's Board of Directors to support its growth and gain insights into the blood-component market. Bloodbuy's platform is crucial in connecting blood centers and hospitals, aiming to reduce waste and improve the efficiency of blood supply management.